H.C. Wainwright raised the firm’s price target on Vera Therapeutics (VERA) to $90 from $85 and keeps a Buy rating on the shares after the company presented findings from its ongoing pivotal ORIGIN 3 study with atacicept. The firm projects the drug to generate risk-adjusted revenues of $56M in 2026, growing to $2.5B by 2033.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics submits BLA for atacicept to FDA
- Vera Therapeutics price target lowered to $52 from $53 at JPMorgan
- Vera Therapeutics’ Atacicept Shows Promising Phase 3 Results and Regulatory Progress, Earning Buy Rating
- Vera Therapeutics Announces Promising Phase 3 Trial Results
- Vera Therapeutics reports ‘positive’ data from ORIGIN Phase 3 trial of atacicept